Zymeworks US929M Theravance Buy at a Discount|Why Both Stocks Fell

The Deal That Pushed Both Stocks Down

Zymeworks Inc. paid US$929 million on June 29 to acquire Theravance Biopharma — at a price both markets immediately rejected. The offer of $17 per share was a 4% discount to Theravance's prior closing price of $17.63, and by Monday morning, both companies were trading lower. That is the first anomaly: an acquirer typically pays a premium sufficient to stop the target's shareholders from voting the deal down, yet Theravance's board simultaneously declared the transaction "achieves the greatest value for Theravance Biopharma shareholders." The company being purchased was not in a position to drive a harder bargain — Theravance had been running a strategic review since early 2024, accelerated in March 2026 when its blood pressure drug ampreloxetine failed its Phase 3 trial, triggering layoffs of half the workforce and an open sale process. A company publicly for sale with its only promising pipeline asset gone is not a company with pricing power. The provisional answer to why both stocks fell lies not in the headline price, but in the financing structure Zymeworks needed to get the deal across the line.

Why OMERS Becoming a Lender Changes the Read

To fund the US$929M deal, Zymeworks put up US$219M of its own cash and drew US$350M from OMERS Life Sciences — the life sciences arm of the Ontario Municipal Employees Retirement System. Zymeworks CFO Kristin Stafford framed this as the deal's strength: a non-recourse note secured solely by Yupelri's U.S. profit share, with no Zymeworks equity component and zero shareholder dilution. Brian Bloom, CEO of Bloom Burton, the Toronto-based life sciences investment bank, read it differently. "OMERS is usually a competitor for royalty transactions," Bloom said in an interview. "OMERS did about 10 deals last year. It's one of most active royalty monetizers globally in pharmaceuticals and many people aren't aware of that." That is the buried tension: OMERS agreed to act as a lender in a deal it would normally win by outright acquisition. Two interpretations follow, and the pool supports both. The first: OMERS assessed the Yupelri royalty stream as steady enough to hold as collateral at 8.25% interest through 2036 — a disciplined lender's bet on recurring cash flow, not a buyer's conviction about upside. The second: Zymeworks required institutional cover to close a US$929M deal it could not finance alone, and OMERS was the only counterparty willing to participate without taking the asset outright. Management's "zero net capital at risk" claim assumes the note is serviced entirely by Yupelri royalties through 2036 — a 10-year assumption on a single drug's commercial trajectory that the market, on June 29, was not willing to accept at face value.

Yupelri's Math and the Milestones That Must Hit

The deal's internal logic depends on three cash flows arriving in sequence. Yupelri generated US$266.6M in U.S. net sales in 2025, growing 12% year over year, with US$62.4M in Q1 2026, representing 7% growth — a slight deceleration that the articles do not explain. Zymeworks receives 35% of U.S. net profits, not net sales, generating approximately US$60-70M annualized under the current run rate. At 8.25% interest on a US$350M note, annual interest alone runs roughly US$29M — meaning Yupelri's 35% profit share must sustain both the debt service and leave residual cash for Zymeworks' own operations while Ziihera, its cancer drug, builds commercial traction. Ziihera generated US$13M in Q1 2026. Royalty Pharma projects US$2.6B in peak sales by 2035, but that projection is nearly a decade away from confirming. The second cash flow is a US$100M milestone expected in Q1 2027, contingent on GSK's global net sales of Trelegy Ellipta exceeding US$3.513B this year. The third is US$2.5B in Irish tax attributes from Theravance — real value only when Zymeworks generates enough taxable income in Ireland to absorb them, which depends on the first two flows delivering. These three flows are sequential, not parallel: each depends on the prior one holding, and none is guaranteed. The verification variable that arrives soonest is Trelegy's full-year 2026 revenue versus that US$3.513B threshold — a binary outcome that either unlocks the Q1 2027 payment or removes it entirely.

The Two Conditions That Decide Whether This Was Overpay

The deal becomes an entry setup for Zymeworks watchers and a hold confirmation for existing shareholders if two conditions land in sequence. First, Trelegy Ellipta's 2026 global net sales clear the US$3.513B threshold, triggering the US$100M Q1 2027 milestone — the earliest concrete proof that Theravance's residual royalty book is worth what Zymeworks paid. Second, Yupelri's U.S. net sales growth rate re-accelerates from the 7% Q1 2026 pace back toward the 12% 2025 rate, demonstrating that the drug can sustain OMERS' collateral value for the 10 years the note runs. The Leerink Research analyst David Risinger, writing in March, estimated Theravance's value at Yupelri's revenue stream plus the $100M Trelegy milestone plus approximately US$400M in cash. Zymeworks is paying US$219M net — less than what Risinger's March floor suggested — if the OMERS note is treated as off-balance-sheet and Theravance's cash covers the rest. That arithmetic is what management means by "zero net capital at risk." The trap: the arithmetic only holds if Yupelri's 35% profit share fully services US$350M at 8.25% for a decade without a generic competitor, a Viatris partnership disruption, or a growth deceleration that impairs the collateral. A holder watches Yupelri's Q2 2026 growth rate when reported, alongside Trelegy's mid-year sales trajectory. A watcher stays out until the Trelegy threshold resolves in Q1 2027 — that single payment arriving confirms the deal's cash-flow spine; its absence breaks the "zero net capital at risk" premise and forces a reassessment of what Zymeworks actually owns.